Abstract
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to $173.4 million to the South Korean biotech company SK Bioscience to further develop a protein nanoparticle vaccine for COVID-19. The commitment is one of the largest for CEPI, which has invested in the early development of 12 COVID-19 vaccines. Its other commitments range from as little as $1 million for Moderna to up to $388 million for Novavax . SK Bioscience’s vaccine, called GBP510, was developed with scientists at the Institute for Protein Design at the University of Washington, who have created a self-assembling protein nanoparticle technology for rapid vaccine design. The nanoparticle is formed by a spherical protein core that displays 60 copies of a portion of the coronavirus spike protein. The resulting spiky ball resembles the coronavirus itself. CEPI has already funded SK Bioscience twice during the pandemic. In December, the nonprofit pledged up to $10 million
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
